Regimens administered to the 1279 patients
| Regimen . | No. of patients . |
|---|---|
| IA group (322 patients, 1991-1997) | |
| Idarubicin + ara-C | 119* |
| Idarubicin + ara-C + G-CSF | 145 |
| Idarubicin + ara-C + lisofylline | 35 |
| Idarubicin + ara-C + G-CSF + ATRA | 23 |
| FA group (600 patients, 1991-1998) | |
| Fludarabine + ara-C | 79 |
| Fludarabine + ara-C + G-CSF | 137 |
| Fludarabine + ara-C + idarubicin | 53 |
| Fludarabine + ara-C + idarubicin + G-CSF | 191 |
| Fludarabine + ara-C + idarubicin + ATRA | 55 |
| Fludarabine + ara-C + idarubicin + G-CSF + ATRA | 85 |
| TA group (357 patients, 1997-1999) | |
| Topotecan + ara-C | 98 |
| Topotecan + ara-C + cyclophosphamide + G-CSF | 259 |
| Regimen . | No. of patients . |
|---|---|
| IA group (322 patients, 1991-1997) | |
| Idarubicin + ara-C | 119* |
| Idarubicin + ara-C + G-CSF | 145 |
| Idarubicin + ara-C + lisofylline | 35 |
| Idarubicin + ara-C + G-CSF + ATRA | 23 |
| FA group (600 patients, 1991-1998) | |
| Fludarabine + ara-C | 79 |
| Fludarabine + ara-C + G-CSF | 137 |
| Fludarabine + ara-C + idarubicin | 53 |
| Fludarabine + ara-C + idarubicin + G-CSF | 191 |
| Fludarabine + ara-C + idarubicin + ATRA | 55 |
| Fludarabine + ara-C + idarubicin + G-CSF + ATRA | 85 |
| TA group (357 patients, 1997-1999) | |
| Topotecan + ara-C | 98 |
| Topotecan + ara-C + cyclophosphamide + G-CSF | 259 |
IA, idarubicin + ara-C; G-CSF, granulocyte colony-stimulating factor; ATRA, all-trans retinoic acid; FA, fludarabine + ara-C; TA, topotecan + ara-C.
35 of the 119 patients received IA in the IA − lisofylline arm of the IA ± lisofylline trial.